ETHA has surged on efficiency and cost benefits, but slowing retail demand and weak liquidity signal short-term downside.

Royalty Pharma is a Buy, with robust growth, valuation discounts, and clear outlooks. Click here to find out why RPRX is a ...

Detailed price information for Bank of America Corp (BAC-N) from The Globe and Mail including charting and trades.